Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 6938-6945

  Okano, Hirokazu ^a   Shinohara, Hisashi ^a   Miyamoto, Akiko ^a   Takaori, Kyoichi ^a   Tanigawa, Nobuhiko ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NONSTEROID ANTIINFLAMMATORY AGENT; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CYCLOOXYGENASE 2; DNA-BINDING PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; STOMACH NEOPLASMS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 6044264970     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0731-03     Document Type: Article

References (46)

1. Stadtlander CT, Waterbor JW. Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis (Lond.) 1999;20:2195-208.
2. Van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002;196:171-9.
3. Tsuji S, Tsuji M, Kawano S, Hori M. Cyclooxygenase-2 up-regulation as a perigenetic change in carcinogenesis. J Exp Clin Cancer Res 2001;20:117-29.
4. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
5. Uefuji K, Ichikura T, Mochizuki H, Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 1998;69:168-72.
6. Saukkonen K, Nieminen O, van Rees B, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-31.
7. Chen CN, Sung C-T, Lin M-T, Lee P-H, Chang K-J. Clinicopathologic association of cyclooxygenase 2 expression in gastric adenocarcinoma. Ann Surg 2001;233:183-8.
8. Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94:451-5.
9. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am. J Physiol 1996;270:G393-400.
10. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
11. Kiguchi K, Carbajal S, Chan K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001;61:6971-6.
12. Vadlamudi R, Mandai M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999;18:305-14.
13. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. J Biol Chem 2002;277:18649-57.
14. Yokota J, Yamamoto T, Miyajima N, et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988;2:283-7.
15. Lemoine NR, Jain S, Silvestre F, et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 1991;64:79-83.
16. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res 1991;51:1034-8.
17. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000;18:2201-9.
18. Roman C, Saha D, Beauchamp R. TGF-β and colorectal carcinogenesis. Microsc Res Tech 2001;52:450-7.
19. Maehara Y, Kakeji Y, Kabashima A, et al. Role of transforming growth factor-β1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999;17:607-14.
20. Lagna G, Hata A, Hemmatibrivanlou A, Massague J. Partnership between DPC4 and Smad proteins in TGF-β signaling pathways. Nature (Lond.) 1996;383:832-6.
21. Xiangming C, Natsugoe S, Takao S, et al. Preserved Smad4 expression in the transforming growth factor β signaling pathway is a favorable prognostic factor in patients with advanced gastric cancer. Clin Cancer Res 2001;7:277-82.
22. Powell SM, Harper JC, Hamilton SR, Robinson CR, Cummings OW. Inactivation of Smad4 in gastric carcinomas. Cancer Res 1997;57:4221-4.
23. Sho J, Sheng H, Aramandla R, et al. Coordinate regulation of cyclooxygenase-2 and TGF-β1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis (Lond.) 1999;20:185-91.
24. Sheng H, Shao J, Hooton EB, Tsujii M, DuBois RN, Beauchamp RD. Cyclooxygenase-2 induction and transforming growth factor β growth inhibition in rat intestinal epithelial cells. Cell Growth Differ 1997;8:463-70.
25. Geiser AG, Kim S, Roberts AB, Sporn MB. Characterization of the mouse transforming growth factor-β1 promoter and activation by the Ha-ras oncogene. Mol Cell Biol 1991;11:84-92.
26. Sheng H, Shao J, Dixon DA, et al. Transforming growth factor-β1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000;275:6628-35.
27. nd English edition. Response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer 2001;4:1-8.
28. Kawasaki H, Toyoda M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during colorectal tumorigenesis. Cancer (Phila.) 2001;91:2026-32.
29. Leung W, To K-F, Ng Y-P, et al. Association between cyclooxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 2001;84:335-9.
30. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9.
31. Saito H, Tsujitani S, Oka S, et al. The expression of transforming growth factor-β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric cancer. Cancer (Phila.) 1999;86:1455-62.
32. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6:519-25.
33. Kawabe A, Shimada Y, Uchida S, et al. Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobactor pylori infection, and vascular endothelial growth factor expression. J Surg Oncol 2002;80:79-88.
34. Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxidase synthase 2. Cell 1995;83:493-501.
35. Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997;15:1-8.
36. Roman CD, Morrow J, Whitehead R, Beauchamp RD. Induction of cyclooxygenase-2 and invasiveness by transforming growth factor bl in immortalized mouse colonocytes expressing oncogenic Ras. J Gastrointest Surg 2002;6:304-9.
37. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998;67:753-91.
38. Chen R-H, Ebner R, Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science (Wash. DC) 1993;260:1335-8.
39. Sheng H, Shao J, O'Mahony CA, et al. Transformation of intestinal epithelial cells by chronic TGF-β1 treatment results in down-regulation of the type II TGF-β receptor and induction of cyclooxygenase-2. Oncogene 1999;18:855-67.
40. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and non-steroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9.
41. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
42. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst (Bethesda) 1998;90:1609-20.
43. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, Dubois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045-51.
44. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-31.
45. Sana D, Datta PK, Sheng H, et al. Synergistic induction of cyclooxygenase-2 by transforming growth factor-β1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia 1999;1:508-17.
46. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.